ClinicalTrials.gg
AvailableNCT07950202Updated Nov 20, 2026

A Protocol for the Expanded Access of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Monotherapy in Participants With Endometrial Cancer (MK-2870-060)

An expanded access record providing Sacituzumab tirumotecan in Endometrial Neoplasms, sponsored by Merck Sharp & Dohme LLC. Available. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Expanded access

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Treatment IND/protocol
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 15 studies in Endometrial Neoplasms by Merck & Co., Inc — 2 open to participants now, 6 under way, 4 of them phase 3. Endometrial Neoplasms · Merck & Co., Inc.

Other kind
Only one
of the 15
Registered
15th of 15
by date

Among the 15 studies in Endometrial Neoplasms by Merck & Co., Inc, this one is the only one of another kind, and was the 15th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 469 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

2 of the 15 studies in Endometrial Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 354 Endometrial Neoplasms studies recruiting now, 264 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Endometrial Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

This trial is an expanded access program (EAP) to give participants the chance to receive sacituzumab tirumotecan (also called sac-TMT) for advanced or recurrent endometrial cancer. Sac-TMT is a trial medicine that is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. Endometrial cancer starts in the tissue inside the uterus (womb). Advanced means the cancer has spread to other parts of the body (metastatic) and cannot be removed with surgery. Recurrent means the cancer came back after treatment.

To join the trial, a participant must meet all these criteria:

  • Surgery or radiation is not an option.
  • They received prior treatment with platinum-based chemotherapy and immunotherapy, separately or in combination, for their cancer. Immunotherapy is a treatment that helps the immune system fight diseases such as cancer.
  • There is no other good treatment choice for their cancer.

Participants will receive sac-TMT until the drug is approved and available in the US or the sponsor ends the EAP. The purpose of this EAP is to provide access to sac-TMT for eligible participants with endometrial cancer.

03

Conditions studied

  • Endometrial Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a -confirmed diagnosis of endometrial cancer
  • Has either measurable or nonmeasurable disease by radiological imaging
  • Has received prior systemic, platinum-based chemotherapy and anti-Programmed Cell Death 1 ()/anti-Programmed Cell Death 1 Ligand 1 (PD-L1) therapy, either separately or in combination, for endometrial cancer
  • Has received up to 3 prior treatment regimens for endometrial cancer
  • Has no satisfactory alternative therapy for the treatment of endometrial cancer, after either disease progression or intolerance on prior treatment

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of pure sarcomas
  • Has recurrence of endometrial cancer >12 months after completing platinum-based therapy administered in the curative-intent setting without any additional platinum-based therapy received in the recurrent setting
  • Requires recurrent drainage of effusions (eg, pleural, ascitic, etc) within 6 weeks before the first dose of EAP treatment
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required , has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments
  • Is expected to require any other form of systemic antineoplastic therapy while receiving sac-TMT
  • Known active central nervous system (CNS) and/or carcinomatous meningitis
  • Active infection requiring systemic therapy other than antiretroviral therapy (ART) for (HIV) and/or antiviral therapy for virus (HBV) or virus (HCV)
  • Is a candidate for an accessible clinical study for sac-TMT or another product, or previously participated in a sac-TMT clinical study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Access details

Study type
Expanded access
Access type
Treatment IND/protocol

Available treatment

  • DrugSacituzumab tirumotecan

    Intravenous (IV) Infusion

    Also known as: sac-TMT, MK-2870, SKB264

06

Where to request access

No study locations are listed for this record.

07

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

08

Registry details

Key details

Study ID
NCT07950202
Responsible party
Sponsor
First posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion